News
BIIB
201.99
+4.56%
8.81
Why Biogen Stock Leaped Nearly 5% Higher Today
Biogen reported its first quarterly earnings report of 2024. The company was more profitable than many expected. The stock of Biogen was up almost 5%. The company's Leqembi drug, approved to slow the progression of Alzheimer's disease, performed well in the first quarter. Biogen reaffirmed its guidance for 2024.
The Motley Fool · 7h ago
US STOCKS-S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
S&P 500 ends higher as markets weigh rising yields, upbeat corporate results. Seven out of 11 sectors make gains; Dow finishes lower while the Nasdaq ends higher. Record auction of a record $70 billion worth of five-year U.S. Treasury bonds pushed bond yields higher. Investors also focused on positive corporate results, especially from technology giants.
Reuters · 9h ago
US STOCKS-Wall St edges lower as rising yields overshadow upbeat corporate results
U.S. Stocks edge lower as rising yields overshadow upbeat corporate results. Seven out of 11 S&P 500 stocks trading lower. Boeing's quarterly revenue falls, but Tesla shares jump 11%. Record auction of record $70 billion of five-year Treasury bonds pushes bond yields higher. Meta Platforms set to report after closing bell; tech giants also expected to report.
Reuters · 11h ago
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Eisai and Biogen's Leqembi is the first drug shown to slow Alzheimer’s progression. The drug faces skepticism among some doctors. Interviews with 20 neurologists and geriatricians revealed concerns about efficacy, costs, and risks of the drug.
Benzinga · 11h ago
Notable Wednesday Option Activity: BIIB, ABNB, HPQ
NASDAQ · 12h ago
BUZZ-U.S. STOCKS ON THE MOVE-Globe Life, EQT, Ribbon Communications
Wall Street's main indexes pared early gains to trade lower on Wednesday. Dow Jones Industrial Average .DJI was down 0.11% at 38,460.49. Top three S&P 500 percentage gainers: Tesla Inc, Hasbro and Visa. Positive earnings across several sectors and rising Treasury yields pressured equities.
Reuters · 12h ago
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?
The S&P 500 fell 0.4% in midday trading in New York. The yield on the 30-year Treasury bond has surged to 4.79%, the highest level since early November. The Japanese yen tumbled to the lowest level since June 1990. Tesla Inc. Posted lower-than-expected results last quarter, but shares rose 10%.
Benzinga · 12h ago
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
NASDAQ · 13h ago
Biogen (BIIB) Q1 2024 Earnings Call Transcript
Biogen (BIIB 4.77%) Q1 2024 Earnings Call will be held on April 24, 2024. The company's president and chief executive officer, Chris Viehbacher, will discuss Biogen's first-quarter 2024 earnings. The conference call is being recorded.
The Motley Fool · 13h ago
US STOCKS-Wall St slips as higher yields offset upbeat corporate earnings
Wall Street's main indexes pared early gains to trade lower on Wednesday. Higher yields offset upbeat corporate earnings across several sectors. Tesla jumps 10.3% after reporting better-than-expected quarterly results. Dow Jones down 0.45%; S&P 500, Nasdaq also down; Dow up 0.14%.
Reuters · 13h ago
BUZZ-U.S. STOCKS ON THE MOVE-MSCI, Globe Life, EQT Corp
The Nasdaq outpaced Wall Street peers on Wednesday. Tesla leads gains among megacap stocks after its quarterly results. The Dow Jones Industrial Average was down 0.35% at 38,368.64. The top three S&P 500 percentage gainers were Hasbro and Texas Instruments.
Reuters · 13h ago
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
Biogen reported first-quarter adjusted EPS of $3.67, up 8%. The company reported sales of $2.29 billion, down 7% year over year. Multiple sclerosis drug Tysabri sales were down to $431.3 million from $472.8 million.
Benzinga · 14h ago
BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024
Biogen reported results for the first quarter of 2024. Biogen reported earnings per share of $3.67. The company reported revenue of $2.29 billion. This was 0.82% worse than the analyst estimate for revenue of  $2.31 billion.
Investorplace · 14h ago
Stocks Settle Mixed on Rising Bond Yields and Tech Strength
US stock indexes on Wednesday settled mixed, with the S&P 500 and Nasdaq 100 posting 1-week highs. Strength in technology stocks was supportive of the overall market, but rising bond yields pressured stocks. Tesla rose more than +12% despite reporting weaker-than-expected Q1 earnings. Q1 corporate earnings take center stage this week with 180 companies scheduled to report.
Barchart · 14h ago
Biogen Up Over 6%, On Track for Largest Percent Increase Since October 2022 -- Data Talk
Biogen Inc. (BIIB) is currently at $204.94, up $11.77 or 6.09% from yesterday's close. Would be highest close since April 9, 2024. Down 20.8% year-to-date; down 53.25% from its all-time closing high of $438.43.
Dow Jones · 15h ago
BUZZ-Biogen rises on Q1 profit beat, surge in Alzheimer's drug sales
Biogen shares up 5.5% to $203.86 in after-hours trading. Drugmaker's Q1 profit beats estimates. Alzheimer's drug Leqembi's global sales triples vs Q4 to $19 million. Biogen developing drug with Japan's Eisai to treat Alzheimer's.
Reuters · 16h ago
US STOCKS-Nasdaq outshines Wall St peers on tech boost, earnings glee
Nasdaq outshines Wall St peers on tech boost, earnings glee. Tesla leads gains among megacap stocks after its quarterly results. Visa rises after Q2 results beat, Snap up after Senate passes TikTok ban bill. Dow down 0.09%, S&P up 0.29%, Nasdaq up0.81%.
Reuters · 16h ago
BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Humana, gold miners
The S&P 500 and the Nasdaq were set to open higher on Wednesday. Tesla leads gains among megacap stocks after its quarterly results. Biogen, Humana, gold miners also rise after upbeat earnings reports. Dow e-minis were down 0.15% in early trading.
Reuters · 16h ago
BUZZ-Sage rises as partner Biogen posts strong Q1 sales of postpartum depression pill
Sage rises as partner Biogen posts strong Q1 sales of postpartum depression pill Zurzuvae. Shares of Sage Therapeutics up 13.1% at $14.65 premarket. Partner Biogen reports $12 mln in Q1 revenue from post-partum depressed pill.
Reuters · 16h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Boston Scientific (BSX) and Biogen (BIIB)
TipRanks · 17h ago
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.